Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Quest Partners LLC
Quest Partners LLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1,386.0% during ...
San Diego Union-Tribune1d
San Diego’s Halozyme withdraws proposed $2.1B acquisition of Evotec
San Diego biotech firm Halozyme Therapeutics is walking back its proposed $2.1 billion acquisition of Evotec, saying the ...
San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer
San Diego biotech firm Halozyme Therapeutics is walking back its proposed $2.1 billion acquisition of Evotec, saying the ...
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its ...
Halozyme withdraws proposal to acquire Evotec for EUR 11.00 per share in cash
Halozyme Therapeutics (HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, ...
Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
Halozyme (HALO) is up 11% to $50.99 in pre-market trading.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...
ENDPOINTS NEWS1d
Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'
Halozyme Therapeutics said Friday that it has pulled its proposal to buy Evotec, a struggling German biotech that Halozyme said was ...
FierceBiotech1d
Halozyme withdraws $2B bid for Evotec after German biotech was 'unwilling to engage'
Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme withdraws $2.1 billion buyout offer for Evotec
Halozyme Therapeutics has withdrawn its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday.
Finanznachrichten1d
Halozyme Therapeutics, Inc.: Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ ...